{"name":"Korean Cancer Study Group","slug":"korean-cancer-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBRNHE1UjNLSGwzdGt2enBTVng0dHNTcXdSMjB5N1A3VWhRR25KTmZFRHgyRXRoaUt6c1kzeF9PajZzaktraEhkMWUxeU1LMHhRVjlMelUzb2RsNm53V1lEZEhnb2g0NV9XQVp3bFFKZ2xYb0p1?oc=5","date":"2026-04-06","type":"trial","source":"Businesskorea","summary":"Hanmi Pharmaceutical Leads Korean Firms in AACR Study Presentations - Businesskorea","headline":"Hanmi Pharmaceutical Leads Korean Firms in AACR Study Presentations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBlWmp1RnlOM2cwNXNhLXJQM0puYThrQnAxajJXU0ROajk4Rnh2aVo1ZjFBNWNCVGpmQ3hsM0EySFRwT3BuMU15dnVPUk9OeWNKWjB3SGd0WVJWOGRQRkJMdG5uVkdqUGl5RU1pa0x30gFyQVVfeXFMTXVZanlKRUFEbEdfNzhqM1BtUlN4VkJiNHZ3SDlUX2kyV3RRQV9ud2p4amdyTjlHOVVwNEEzLW9zMDl6cW9icThJSzVVYVdVYkRFaG5nbzc0SW01R0kzeE1FWWo3anRfeGlZNTlNU002aFF3?oc=5","date":"2026-04-03","type":"deal","source":"koreabiomed.com","summary":"AbbVie deepens SNUH partnership to accelerate early-stage cancer drug development - koreabiomed.com","headline":"AbbVie deepens SNUH partnership to accelerate early-stage cancer drug development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPb0ZCY1FHbVRKMjJmWDdhY2pLQjlXRkpUZlg2TXAyT2tnMnRudVpaMlZNRVpYZk41TGJGb0ljcnl2MElnQUhEWlpzRVQ1dDJlT1VqeTBJdXAzakFCZE5UeTY3SjdhbjJjQzhwYjRRM0xibWFvUnhEZjRMeXY0eGxxTkl5RTdwZnM5UEx6YWdVdWprUWNtVUM2d0hIemItdC1pOUptNw?oc=5","date":"2026-04-01","type":"pipeline","source":"TradingView","summary":"Medivir 2025 Annual Report published - TradingView","headline":"Medivir 2025 Annual Report published","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5vcGpkMEpxdExBLVM0U0FjR1g1YUFfYWlYMDBDZHQydU9Ydll5SW1wQVZ4dGhMWXRWbDZlLWdqb2FOeXd5ZVFLSFlMU3ZsWVBMZkc1WjZFaXg4dl8zcnhGOEozZ0o1SlVlRzRYSWhn0gFyQVVfeXFMTmV1dHRwMlBEZTQwcTRiSXktNGo4ZmxiUFE4STIxNS11ZGN3MXluclBSd3FXaGR5R2wyYlNYX1hKR2xxVDlOcEt4SzZSWVNMTVFDanlWV2VMSGZiTHdCZHVpTFpPVWVDa1dYbVZZQldJekFR?oc=5","date":"2026-03-24","type":"regulatory","source":"koreabiomed.com","summary":"AstraZeneca’s Imfinzi wins Korea approval for perioperative gastric cancer treatment - koreabiomed.com","headline":"AstraZeneca’s Imfinzi wins Korea approval for perioperative gastric cancer treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5ud3JLTTdmcURoMGRIenE2Um42SWxIZnN1bHZGTF9Za09kQ1hBWjk4VlB0YTdwUXg5S2tETHpGZ2puTElyQ3FfUXUyalFWbGhSUlZOVU9LWWt1OVVfa2V4ZHVpeGFWVUc5MnBpX3FR0gFyQVVfeXFMTlRXNUxWMTNDU1FwUHpILXh6RTMyT3h6SWJJU0dTTWN1S0wxVlRjek1FRGdXQ3FkUnJmTHRfck9CVjhiNVZyMXdacW9XY3RqUXBkYzM2UEdnaDgzVDBLWmpNQUt6SlNnaV90VnVYZk1zMTdn?oc=5","date":"2025-12-18","type":"trial","source":"koreabiomed.com","summary":"Breast cancer costs Korea $98 million a year: Novartis study - koreabiomed.com","headline":"Breast cancer costs Korea $98 million a year: Novartis study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5GZ0FDdS1RQnRpRC1uX184LURLWEJzbWJXZVpqd0tvU0JpNlhVelpldWVtVTg2OTNYdmZ0MkdXaTFiN2JlUFJKYjhfZ3MySVU1ZHJHS1hoa1N1QzNRYkdWay04TlRsVlVEZGFWSVpR0gFyQVVfeXFMTnBMU1IxRHIzYnJaZ1dLbnJRTTd0N2VuWk9oVk9xbkxwS05DcktEeHVRcmVsZzdWOHdSZEJHZ09wSC1aRkpxVElsampMZVdSNUI2dWg4N2x1czY0aFgydzZkcWk0TFBqR2N0Y05FYlJRb1BR?oc=5","date":"2025-10-20","type":"pipeline","source":"koreabiomed.com","summary":"[ESMO 2025] Enhertu outperforms Kadcyla in HER2-positive early breast cancer - koreabiomed.com","headline":"[ESMO 2025] Enhertu outperforms Kadcyla in HER2-positive early breast cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFA3UjkwekNBY1RiaXZldjdMVDNzUUVIaE1qRW9OSXRwbGlDcU5QVFdMX1dFTDhZazN4STd6RW1qa0dKV19wZGlSdmU3dFp1NW52WFVaRnp5dUxCOUFudU5sSkhxcGJTbmpvcFVROXh3?oc=5","date":"2025-09-11","type":"pipeline","source":"KED Global","summary":"J Ints Bio unveils 4th-generation targeted anti-cancer drug candidate - KED Global","headline":"J Ints Bio unveils 4th-generation targeted anti-cancer drug candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE5Cc09EVnhsTlo2a2hWUS04aEhWYmlQbUtZQjNtcEgxRUJZZG1ldXpicUlhbzVvWHhfd2lfZGxwRnZTSE9weE1PNjQ0LW5kYm0xaWREaVdTM29RbEJDb2ZDQVhfdzFIY0hGek5xaWhBeENFQzFqcENF?oc=5","date":"2025-08-26","type":"pipeline","source":"Labiotech.eu","summary":"5 South Korean biotech companies making global waves - Labiotech.eu","headline":"5 South Korean biotech companies making global waves","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1XZGFTV0pzUS1KbW5ZdjZ4eUhTWWpBVGtJb0EtSHBkZFN3V183QU1LY1BRR3ZFcmhjZjU3Z2xvUld6aDh2UzlaZFMwZ1p2UGxhbDNBbmFtX3pXSVNQdFBj?oc=5","date":"2025-04-23","type":"pipeline","source":"Nature","summary":"Four rising stars at the forefront of cancer research - Nature","headline":"Four rising stars at the forefront of cancer research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE92SGpRY2RCOUg2ZEJfWHVWb1dhT3hoZkNuRHkzQ2otaWRINEM1WVl0WjBka0syOVRlTlBEd2Ffc0tqbEFDSmNjOEJod04xOV9lTjFiRnZmcXZJMy1jNWcw?oc=5","date":"2024-01-03","type":"regulatory","source":"Nature","summary":"Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis | Scientific Reports - Nature","headline":"Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis | Scientific Reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE10R1dpdUFmTTFfc3VVbFFMUEdENUVZcWcyOWlRVVBHSlRxal9rSUJxRERQQjAwU2FIeFRvLUo1emRNNS1MemZUMkdXdmF2djYzT2dldGw1M25wa0Nid1lQVzNR?oc=5","date":"2022-09-27","type":"pipeline","source":"Roche","summary":"Korea: Establishing a consortium focused on expanded access to targeted treatment options - Roche","headline":"Korea: Establishing a consortium focused on expanded access to targeted treatment options","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOc3F2eGVneHFlY3NQaHJqbXBJSC0zbXoxY1ZURk94ZENScTc1Z1h1Z1U2NUtNcDRlMUVsczVCYjBtUFJKTzR1b1ZxbmxtT0xVODNxejBGbUU0eDhoX3E2ZUNmVXMzWG9Jcnhqc1BNS1dMVGlmSWZ5RVlwS2FBTjdWbjE1NmlnanpiT0xjRUtPOHp2MmM?oc=5","date":"2022-08-22","type":"pipeline","source":"Frontiers","summary":"Corporate social responsibility of pharmaceutical industry in Korea - Frontiers","headline":"Corporate social responsibility of pharmaceutical industry in Korea","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}